In a 2022 study, Sodhi’s group identified ANGPTL4 as a potential culprit in nonresponse to anti-VEGF drugs, which are ...

A Johns Hopkins study reveals that anti-VEGF treatments for wet AMD may unintentionally elevate ANGPTL4, a protein that ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...

Advertisement To combat this, doctors prescribe medications that slow the growth of new blood vessels, called anti-VEGF ...

An RNA-editing gene therapy has been developed that switches off the key driver of common eye conditions affecting diabetics ...

To combat this, doctors prescribe medications that slow the growth of new blood vessels, called anti-VEGF (vascular ...

A study from researchers at Wilmer Eye Institute, Johns Hopkins Medicine explains not only why some patients with wet ...

Study points to approach to improving anti-VEGF therapy for all wet AMD patients, and help subset of patients who lose vision ...

and potential to improve visual acuity and reduce anti-VEGF injections. AI/ML-driven HG-PRECISE platform enabled the ...

MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the ...